130 related articles for article (PubMed ID: 35170793)
1. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Molica S; Giannarelli D; Visentin A; Reda G; Sportoletti P; Frustaci AM; Chiarenza A; Ciolli S; Vitale C; Laurenti L; De Paoli L; Murru R; Gentile M; Moia R; Rigolin GM; Levato L; Giordano A; Del Poeta G; Stelitano C; Deodato M; Ielo C; Noto A; Guarente V; Coscia M; Tedeschi A; Gaidano G; Cuneo A; Foa' R; Trentin L; Mauro FR
Am J Hematol; 2022 May; 97(5):E176-E180. PubMed ID: 35170793
[No Abstract] [Full Text] [Related]
2. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
3. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Woyach J; Tedeschi A; Munir T; Siddiqi T; Hillmen P; Byrd JC; Ghia P; Mulligan SP; Dai S; Amaya-Chanaga CI; Dean JP; O'Brien SM; Barr PM
Leuk Lymphoma; 2021 Dec; 62(13):3278-3282. PubMed ID: 34384312
[No Abstract] [Full Text] [Related]
4. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Baumann T; Montserrat E
Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
[No Abstract] [Full Text] [Related]
5. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
[No Abstract] [Full Text] [Related]
6. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
İskender G; İskender D; Ertek M
Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
[No Abstract] [Full Text] [Related]
7. Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
Molica S; Allsup DJ; Polliack A
Leuk Lymphoma; 2022 Aug; 63(8):1771-1773. PubMed ID: 35703117
[No Abstract] [Full Text] [Related]
8. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
[No Abstract] [Full Text] [Related]
9. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
10. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
Khountham S; Shindiapina P; Mo X; Lachowiez C; Wiczer T; Mousa L; Rogers KA; Andritsos LA; Woyach JA; Byrd JC; Spurgeon SE; Awan FT
Leuk Lymphoma; 2021 Mar; 62(3):716-721. PubMed ID: 33210562
[No Abstract] [Full Text] [Related]
11. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Brochard J; Morio F; Mahe J; Le Pape P; Guimard T; Mahe B; Leterrier M; Morrier M; Raffi F; Boutoille D
Med Mal Infect; 2020 Nov; 50(8):742-745. PubMed ID: 32777360
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU
Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib.
Choi JH; Hur JY; Won YW
Cancer Res Treat; 2023 Apr; 55(2):704-705. PubMed ID: 36652902
[No Abstract] [Full Text] [Related]
15. Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
Coppola PE; Broccoli A; Argnani L; Casadei B; Stefoni V; Bertuzzi C; Sabattini E; Zinzani PL
Leuk Lymphoma; 2021 Dec; 62(14):3540-3543. PubMed ID: 34348068
[No Abstract] [Full Text] [Related]
16. Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
Ysebaert L; Quinquenel A; Bijou F; Ferrant E; Michallet AS;
Eur J Cancer; 2020 Aug; 135():170-172. PubMed ID: 32585590
[No Abstract] [Full Text] [Related]
17. Ibrutinib-Induced Skin Rash.
Kirar S; Gogia A; Gupta R; Mallick S
Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
[No Abstract] [Full Text] [Related]
18. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
DiSogra KY; Tran T; Arnall JR; Janes A; Moore DC; Park SI
J Oncol Pharm Pract; 2021 Jul; 27(5):1265-1269. PubMed ID: 33106104
[TBL] [Abstract][Full Text] [Related]
20. Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
Martín-Moro F; García-Cosío M; Marquet-Palomanes J; López-Gutiérrez M; Pian-Arias H; López-Jiménez FJ
Ann Hematol; 2022 Jan; 101(1):213-215. PubMed ID: 33423076
[No Abstract] [Full Text] [Related]
[Next] [New Search]
